Tag: FDA premarket approval
-
NHS-Galleri’s Primary Endpoint Was Negative. A Day Later, FDA’s Panel Voted Yes. They Were Answering Different Questions, About Different Devices
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. This post covers a peer-reviewed randomized trial and a public regulatory advisory-committee record for a listed company’s screening test. Every number below is attributed to its source tier — peer-reviewed abstract, FDA public…
